Latest news with #CART-cell
Business Wire
3 days ago
- Health
- Business Wire
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 2030
CHICAGO--(BUSINESS WIRE)--Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. The CAR T Vision is for every eligible patient to have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. 'Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,' said Miguel Perales, MD, Chief, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center (MSK); Past President, American Society for Transplantation and Cellular Therapy (ASTCT); and Co-Chair, CAR T Vision Steering Committee. 'When it comes to treating these potentially deadly cancers, every minute counts. That is why we established CAR T Vision with recommendations for interventions that, when adopted and scaled, will help many more eligible patients get the opportunity for cure within the next five years.' The roadmap report, developed by an independent Steering Committee comprised of leadership from top North American and European patient advocacy groups, medical society organizations, academic and community treatment centers, health technology assessment, policy, and other subject matter experts, provides the foundations for advocacy and action by local stakeholders to address the specific access challenges patients face in different geographies. Building on the report, expert Working Groups will be established to translate the Vision into concrete, measurable actions, including specific recommendations and a measurement framework to track progress. 'Limited awareness of CAR T-cell therapy, low referrals, hospital capacity challenges, and funding and reimbursement are among the barriers that either prevent people from accessing CAR T-cell therapy altogether or cause delays that advance a patient's cancer beyond the point of treatment eligibility. In short, these barriers cost lives,' said Anna Sureda, MD, PhD, Clinical Hematologist, Professor and Cell Therapy Researcher; and Co-Chair, CAR T Vision Steering Committee. 'We call on every stakeholder and organization with the ability to help shape better patient outcomes—policymakers, health system leaders, payors, healthcare providers, patient advocates, and industry—to join the growing coalition of Vision endorsers and help ensure every eligible patient has the opportunity for cure with CAR T-cell therapy.' Making CAR T Vision a reality will require the coming together of a complex ecosystem of partners, each with their own unique role to play. To learn more about CAR T Vision, review the roadmap report and join the coalition, visit About CAR T-cell therapy and CAR T Vision CAR T-cell therapy involves engineering a person's own immune cells to target and treat cancer and is currently approved for certain types of aggressive blood cancers, enabling some patients to remain cancer free for more than five years. 4,5,6,7 The CAR T Vision is for every eligible patient to have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. The CAR T Vision Steering Committee includes leadership from top North American and European patient advocacy groups, medical society organizations, academic and community treatment centers, health technology assessment, policy, and other subject matter experts. The new roadmap report details the challenges CAR T Vision aims to resolve through multidisciplinary collaboration and the urgent actions needed to make the Vision a reality. The report and initial activities of the CAR T Vision Steering Committee have been funded by Gilead Sciences and Kite, as the inaugural supporter of CAR T Vision. Report content has been reviewed by Gilead Sciences and Kite. However, the Steering Committee has editorial control of the CAR T Vision and its outputs, including the report. Dr. Perales has financial interests related to Gilead Sciences and Kite. To learn more about CAR T Vision, review the report and join the growing coalition of endorsers, visit 1 Kaltwasser J. Investigators set sights on optimizing CAR T-cell therapy in lymphoma. OncLive. 2022. Available online: 2 Chuhara, D, Liao, L, et al. Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma. Blood. 2023, September 21. 3 Canales Albendea MÁ, Canonico PL, Cartron G, et al. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries. Front Med (Lausanne). 4 Abramson J, Palomba ML, Gordon LI, et al. Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). Blood. 2024;144(1):3125. 5 Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893. PMID: 36821768; PMCID: PMC10646788. 6 Rives S, Maude S, Hiramatsu H et al. S112: TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): FINAL ANALYSES FROM THE ELIANA STUDY. HemaSphere 6():p 13-14, June 2022. | DOI: 10.1097/ 7 Xu J, Wang BY, Yu SH, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024 Apr 24;17(1):23. doi: 10.1186/s13045-024-01530-z. PMID: 38659046; PMCID: PMC11040812.
Al Etihad
21-05-2025
- Health
- Al Etihad
Newly available CAR T-cell therapy cuts cancer treatment cost by 90%
22 May 2025 02:00 ABU DHABI (ALETIHAD)Burjeel Medical City in Abu Dhabi has announced a major medical breakthrough with the development of an innovative CAR T-cell therapy for blood cancers, which could reduce treatment costs by up to 90 advancement marks a significant step towards localising biopharmaceutical industries, reinforcing the UAE's position as a regional hub for cellular therapies and medical innovation, while also enhancing healthcare and economic to Emirates News Agency (WAM) on the sidelines of the Make it in the Emirates forum at the Abu Dhabi National Exhibition Centre (ADNEC), Dr. Ajlan Al Zaki, Director of the Centre for Haematology, Oncology and Cellular Therapy at Burjeel Hospital in Abu Dhabi, described the event as an ideal platform to introduce this advanced therapy involves collecting T-cells from the patient, genetically modifying them in a laboratory to recognise and attack cancer cells, then reinfusing them into the patient's Zaki said the forum offers a strategic opportunity to showcase the UAE's capabilities in locally manufacturing CAR T-cells and exploring export potential for this technology to regional and international markets. He noted that this approach exemplifies the integration of science and biotechnology, supporting the knowledge economy and building a sustainable healthcare highlighted that the hospital's success in reducing treatment costs by up to 90 percent is unprecedented in the region, and strengthens the UAE's standing as a regional centre for advanced therapies. The achievement also paves the way for greater global scientific collaboration and reflects the country's significant progress in the medical Zaki, who previously held research and clinical roles at Stanford University and the MD Anderson Cancer Center, expressed his commitment to leveraging his expertise to provide effective and affordable cancer treatments across the UAE and the wider region, while raising awareness of CAR T-cell therapy for difficult-to-treat blood explained that CAR T-cell therapy is a form of personalised, precision medicine usually administered in a single session, with promising recovery rates. This represents a paradigm shift in the future of cancer care in the UAE, and strengthens Abu Dhabi's role as a regional centre for clinical research and cancer treatment CAR T-cell initiative, he added, demonstrates the UAE's capacity to localise advanced biotechnologies, empower national talent, and bridge scientific research with precision medicine and personalised the treatment was initially designed for blood cancers such as leukaemia and lymphoma, research is expanding its application to solid tumours, including breast, pancreatic and lung cancers, as well as complex brain tumours like glioblastoma and metastatic cancers resistant to conventional Zaki also emphasised the growing role of artificial intelligence in genomic analysis and precise molecular target identification, along with the use of cutting-edge gene editing tools like CRISPR to enhance cell engineering. He pointed to the UAE's collaborative efforts with scientific partners and non-profit institutions such as Caring Cross to manufacture these therapies locally, helping to make them more widely accessible across regional medical centres, rather than limited to a handful of global facilities. Source: Aletihad - Abu Dhabi
The Guardian
17-02-2025
- Health
- The Guardian
Woman who had pioneering cancer treatment 18 years ago still in remission
A woman treated with a pioneering type of immunotherapy for a solid tumour has been in remission for more than 18 years with no further treatments, experts have revealed. The therapy involves taking T-cells, a type of white blood cell, from a patient and genetically engineering them to target and kill cancer cells. These modified T-cells are grown in a laboratory and then infused back into the patient. Known as CAR (chimeric antigen receptor) T-cell therapy, the approach has proved particularly successful in treating certain types of blood cancers. Next-generation forms of the therapy have been approved for such cancers in countries including the US and UK. However, response rates have been less encouraging in solid tumours, with long-term outcomes unclear. Now researchers have reported the longest known survival after CAR T-cell therapy for an active cancer, revealing a woman who was treated as a child 18 years ago has remained cancer free. Crucially, the therapy was given for a type of solid tumour called neuroblastoma, a rare cancer of the nerve tissue that develops in children. Prof Helen Heslop, co-author of the research from Baylor College of Medicine in Houston, Texas, says the trial was one of the earliest to use CAR T-cell therapy for cancer. 'It's nice to have such long-term follow-up and to see that even if it was a very early CAR T-cell – and there's been a lot of work to make them better – we were still able to see a clinical remission that's been sustained for this long, so that she's grown up and is leading a normal life,' Heslop says. Writing in the journal Nature Medicine, Heslop and colleagues report how they recruited 19 children to take part in a phase 1 clinical trial of CAR T-cell therapy for neuroblastoma between 2004 and 2009. Over seven years that followed the therapy, 12 patients died due to relapsed neuroblastoma. Among the seven that survived beyond this point, five were cancer-free when given the CAR T-cell therapy but had previously been treated for neuroblastoma using other approaches and were at high risk of relapse. All five were disease-free at their last follow-up, between 10 and 15 years after the CAR T-cell therapy, although the team note they may already have been cured when the therapy was administered. The other two surviving patients had cancer that was actively growing or spreading when they received CAR T-cell therapy, but subsequently went into complete remission. One of these patients stopped participating in follow-up sessions eight years after treatment, but the other continued and has remained cancer-free more than 18 years. 'She has never required any other therapy and is likely the longest-surviving patient with cancer who received CAR-T therapy,' the team write. 'Encouragingly, she has subsequently had two full-term pregnancies with normal infants.' The team add the modified T-cells were still detectable in some patients after more than five years. Heslop says that, while it is not known for sure, it could be that CAR T-cells that persist are able to tackle the cancer should it return. Heslop adds that newer forms of CAR T-cell therapy have shown a greater response in recent trials for neuroblastoma, and may also help tackle some types of brain tumour in children. Karin Straathof, the associate professor in tumour immunology at UCL's Cancer Institute, who was not involved in the new study, says the results are beyond encouraging. 'This is really a solid demonstration that in solid cancers you can achieve complete responses, but also what we want really – and particularly for children's cancers – long-lasting complete responses,' she says. But Straathof says further work is needed, adding: 'What we now are trying to focus on is understanding why does it work in some patients and why [it] doesn't work in others, and what we can learn from that to make better designs of these chimeric antigen receptors.'
